http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 15 Oct 2026 16:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Myriad+Genetics+to+Release+Third+Quarter+2026+Financial+Results+on+November+4%2C+2026/27193315.html <p>SALT LAKE CITY, Oct. 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=p0otS-Qya_lRzyaHJCbR0m_jvQl8ezFqtJKy7efOykpDs412_PciWpreTg1TFjCLqqJxmJ0zBi7t8Hb81kr9W-VYMTmKLbGHzmNvTguxDf8=" rel="nofollow" target="_blank">Myriad Genetics, Inc.</a>, (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2026 earnings conference call at 4:30 pm ET on Wednesday, November 4, 2026. The company’s quarterly earnings will be released the same day after market close. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2026.</p> <p>A live webcast of the conference call can be accessed on Myriad’s Investor Relations website at <a href="https://www.globenewswire.com/Tracker?data=fzqvlTdUANz0p_tVEbZ8lz8cARlQMfSAwNqvYKu8m5CSqlrmAwGkHRkttx0-W3nbm2a6qw_T9FhSwUzDIwEn35VDVacd57sn_n6NYhRYbRtYpfOEh6y-_g_P-iSP1jqCzYX46wiW2PQv-dxg1jJSp-Qd6xuppQF_V-gjputbbzag8udDMdFwmziwlkCr5S_YkHbekrb5poCUvG09zo2zhgZM8-fe2I0H_6rw5fOfC4KnhzAldzLACJ5wcxe2R0FMZEDnQo2Nw_ExGdv0YdL4WA==" rel="nofollow" http://www.streetinsider.com/Press+Releases/Myriad+Genetics+to+Release+Third+Quarter+2026+Financial+Results+on+November+4%2C+2026/27193315.html Thu, 15 Oct 2026 16:05:00 -0400 MYGN http://www.streetinsider.com/Globe+Newswire/Myriad+Genetics+to+Release+Third+Quarter+2026+Financial+Results+on+November+4%2C+2026/27193315.html <p>SALT LAKE CITY, Oct. 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=p0otS-Qya_lRzyaHJCbR0m_jvQl8ezFqtJKy7efOykpDs412_PciWpreTg1TFjCLqqJxmJ0zBi7t8Hb81kr9W-VYMTmKLbGHzmNvTguxDf8=" rel="nofollow" target="_blank">Myriad Genetics, Inc.</a>, (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2026 earnings conference call at 4:30 pm ET on Wednesday, November 4, 2026. The company’s quarterly earnings will be released the same day after market close. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2026.</p> <p>A live webcast of the conference call can be accessed on Myriad’s Investor Relations website at <a href="https://www.globenewswire.com/Tracker?data=fzqvlTdUANz0p_tVEbZ8lz8cARlQMfSAwNqvYKu8m5CSqlrmAwGkHRkttx0-W3nbm2a6qw_T9FhSwUzDIwEn35VDVacd57sn_n6NYhRYbRtYpfOEh6y-_g_P-iSP1jqCzYX46wiW2PQv-dxg1jJSp-Qd6xuppQF_V-gjputbbzag8udDMdFwmziwlkCr5S_YkHbekrb5poCUvG09zo2zhgZM8-fe2I0H_6rw5fOfC4KnhzAldzLACJ5wcxe2R0FMZEDnQo2Nw_ExGdv0YdL4WA==" rel="nofollow" http://www.streetinsider.com/Globe+Newswire/Myriad+Genetics+to+Release+Third+Quarter+2026+Financial+Results+on+November+4%2C+2026/27193315.html Thu, 15 Oct 2026 16:05:00 -0400 MYGN http://www.streetinsider.com/Analyst+PT+Change/Myriad+Genetics+%28MYGN%29+PT+Raised+to+%244.50+at+TD+Cowen/27178884.html TD Cowen analyst Kyle Boucher raised the price target on Myriad Genetics (NASDAQ: MYGN) to $4.50 (from $4.00) while maintaining a rating. http://www.streetinsider.com/Analyst+PT+Change/Myriad+Genetics+%28MYGN%29+PT+Raised+to+%244.50+at+TD+Cowen/27178884.html Tue, 13 Oct 2026 09:32:13 -0400 MYGN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MYRIAD+GENETICS+INC+++++++For%3A+Oct+06/27171715.html si-local-file:///var/storage/secattach/20261009/27171715.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MYRIAD+GENETICS+INC+++++++For%3A+Oct+06/27171715.html Fri, 09 Oct 2026 16:16:00 -0400 MYGN http://www.streetinsider.com/Corporate+News/Myriad+Genetics+and+SOPHiA+Genetics+team+up+on+prostate+cancer+test/27164728.html <p>Myriad Genetics (NASDAQ: MYGN) and SOPHiA Genetics (NASDAQ: SOPH) announced a collaboration to advance a prostate cancer-specific genomic instability score (PrGIS) technology, working alongside AstraZeneca (NYSE: AZN) to support precision oncology approaches.</p><p>PrGIS is a biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. Myriad developed the technology using its MyChoice CDx test, currently available as a companion diagnostic in ovarian cancer, which will produce the PrGIS score as the company pursues prostate cancer as a new indication.</p><p>The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines http://www.streetinsider.com/Corporate+News/Myriad+Genetics+and+SOPHiA+Genetics+team+up+on+prostate+cancer+test/27164728.html Thu, 08 Oct 2026 09:01:21 -0400 AZN MYGN SOPH http://www.streetinsider.com/Corporate+News/Myriad+Genetics+and+SOPHiA+Genetics+team+up+on+prostate+cancer+test/27164728.html <p>Myriad Genetics (NASDAQ: MYGN) and SOPHiA Genetics (NASDAQ: SOPH) announced a collaboration to advance a prostate cancer-specific genomic instability score (PrGIS) technology, working alongside AstraZeneca (NYSE: AZN) to support precision oncology approaches.</p><p>PrGIS is a biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. Myriad developed the technology using its MyChoice CDx test, currently available as a companion diagnostic in ovarian cancer, which will produce the PrGIS score as the company pursues prostate cancer as a new indication.</p><p>The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines http://www.streetinsider.com/Corporate+News/Myriad+Genetics+and+SOPHiA+Genetics+team+up+on+prostate+cancer+test/27164728.html Thu, 08 Oct 2026 09:01:21 -0400 AZN MYGN SOPH http://www.streetinsider.com/Corporate+News/Myriad+Genetics+and+SOPHiA+Genetics+team+up+on+prostate+cancer+test/27164728.html <p>Myriad Genetics (NASDAQ: MYGN) and SOPHiA Genetics (NASDAQ: SOPH) announced a collaboration to advance a prostate cancer-specific genomic instability score (PrGIS) technology, working alongside AstraZeneca (NYSE: AZN) to support precision oncology approaches.</p><p>PrGIS is a biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. Myriad developed the technology using its MyChoice CDx test, currently available as a companion diagnostic in ovarian cancer, which will produce the PrGIS score as the company pursues prostate cancer as a new indication.</p><p>The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines http://www.streetinsider.com/Corporate+News/Myriad+Genetics+and+SOPHiA+Genetics+team+up+on+prostate+cancer+test/27164728.html Thu, 08 Oct 2026 09:01:21 -0400 AZN MYGN SOPH http://www.streetinsider.com/Press+Releases/SOPHiA+GENETICS+and+Myriad+Genetics+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164650.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4792652-1&amp;h=2487028299&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fwww.sophiagenetics.com%2F___.YzJ1Om15cmlhZGdlbmV0aWNzOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmMwYjkyZTg4NmQ1ZGJiNjJlZTczMzJjZWY5MzhjNWZlOjc6OTcxZjo0YjU3ZmM5MTM4NjlmMmNlNzBhNjBkMDAzZjZiNmViMmQ4NmJmYmMzZGVkMDU1NDQ0N2JlNzYwNzk0MTAwODVhOnA6RjpO&amp;a=SOPHiA+GENETICS" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:SOPH" idsrc="xmltag.org" >SOPHiA GENETICS</span></a> (NASDAQ: SOPH) and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4792652-1&amp;h=1870734191&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fmyriad.com%2F___.YzJ1Om15cmlhZGdlbmV0aWNzOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmMwYjkyZTg4NmQ1ZGJiNjJlZTczMzJjZWY5MzhjNWZlOjc6OTY5MjpjNWExMzdiOWVkOTgyY2ZmYmI3YmNhMzBhODYxMzI1MjBkYTM1ZTY3ZGFiMzhjYjVjODgwYWY3N2ZjNTEyMjA5OnA6RjpO&amp;a=Myriad+Genetics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:MYGN" idsrc="xmltag.org" >Myriad Genetics, Inc.</span></a>, (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with <span value="NYSE:AZN" idsrc="xmltag.org" >AstraZeneca</span> (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims http://www.streetinsider.com/Press+Releases/SOPHiA+GENETICS+and+Myriad+Genetics+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164650.html Thu, 08 Oct 2026 09:00:00 -0400 AZN MYGN SOPH http://www.streetinsider.com/PRNewswire/SOPHiA+GENETICS+and+Myriad+Genetics+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164650.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4792652-1&amp;h=2487028299&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fwww.sophiagenetics.com%2F___.YzJ1Om15cmlhZGdlbmV0aWNzOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmMwYjkyZTg4NmQ1ZGJiNjJlZTczMzJjZWY5MzhjNWZlOjc6OTcxZjo0YjU3ZmM5MTM4NjlmMmNlNzBhNjBkMDAzZjZiNmViMmQ4NmJmYmMzZGVkMDU1NDQ0N2JlNzYwNzk0MTAwODVhOnA6RjpO&amp;a=SOPHiA+GENETICS" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:SOPH" idsrc="xmltag.org" >SOPHiA GENETICS</span></a> (NASDAQ: SOPH) and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4792652-1&amp;h=1870734191&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fmyriad.com%2F___.YzJ1Om15cmlhZGdlbmV0aWNzOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmMwYjkyZTg4NmQ1ZGJiNjJlZTczMzJjZWY5MzhjNWZlOjc6OTY5MjpjNWExMzdiOWVkOTgyY2ZmYmI3YmNhMzBhODYxMzI1MjBkYTM1ZTY3ZGFiMzhjYjVjODgwYWY3N2ZjNTEyMjA5OnA6RjpO&amp;a=Myriad+Genetics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:MYGN" idsrc="xmltag.org" >Myriad Genetics, Inc.</span></a>, (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with <span value="NYSE:AZN" idsrc="xmltag.org" >AstraZeneca</span> (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims http://www.streetinsider.com/PRNewswire/SOPHiA+GENETICS+and+Myriad+Genetics+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164650.html Thu, 08 Oct 2026 09:00:00 -0400 AZN MYGN SOPH http://www.streetinsider.com/Press+Releases/SOPHiA+GENETICS+and+Myriad+Genetics+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164650.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4792652-1&amp;h=2487028299&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fwww.sophiagenetics.com%2F___.YzJ1Om15cmlhZGdlbmV0aWNzOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmMwYjkyZTg4NmQ1ZGJiNjJlZTczMzJjZWY5MzhjNWZlOjc6OTcxZjo0YjU3ZmM5MTM4NjlmMmNlNzBhNjBkMDAzZjZiNmViMmQ4NmJmYmMzZGVkMDU1NDQ0N2JlNzYwNzk0MTAwODVhOnA6RjpO&amp;a=SOPHiA+GENETICS" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:SOPH" idsrc="xmltag.org" >SOPHiA GENETICS</span></a> (NASDAQ: SOPH) and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4792652-1&amp;h=1870734191&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fmyriad.com%2F___.YzJ1Om15cmlhZGdlbmV0aWNzOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmMwYjkyZTg4NmQ1ZGJiNjJlZTczMzJjZWY5MzhjNWZlOjc6OTY5MjpjNWExMzdiOWVkOTgyY2ZmYmI3YmNhMzBhODYxMzI1MjBkYTM1ZTY3ZGFiMzhjYjVjODgwYWY3N2ZjNTEyMjA5OnA6RjpO&amp;a=Myriad+Genetics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:MYGN" idsrc="xmltag.org" >Myriad Genetics, Inc.</span></a>, (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with <span value="NYSE:AZN" idsrc="xmltag.org" >AstraZeneca</span> (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims http://www.streetinsider.com/Press+Releases/SOPHiA+GENETICS+and+Myriad+Genetics+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164650.html Thu, 08 Oct 2026 09:00:00 -0400 AZN MYGN SOPH http://www.streetinsider.com/PRNewswire/SOPHiA+GENETICS+and+Myriad+Genetics+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164650.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4792652-1&amp;h=2487028299&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fwww.sophiagenetics.com%2F___.YzJ1Om15cmlhZGdlbmV0aWNzOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmMwYjkyZTg4NmQ1ZGJiNjJlZTczMzJjZWY5MzhjNWZlOjc6OTcxZjo0YjU3ZmM5MTM4NjlmMmNlNzBhNjBkMDAzZjZiNmViMmQ4NmJmYmMzZGVkMDU1NDQ0N2JlNzYwNzk0MTAwODVhOnA6RjpO&amp;a=SOPHiA+GENETICS" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:SOPH" idsrc="xmltag.org" >SOPHiA GENETICS</span></a> (NASDAQ: SOPH) and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4792652-1&amp;h=1870734191&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fmyriad.com%2F___.YzJ1Om15cmlhZGdlbmV0aWNzOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmMwYjkyZTg4NmQ1ZGJiNjJlZTczMzJjZWY5MzhjNWZlOjc6OTY5MjpjNWExMzdiOWVkOTgyY2ZmYmI3YmNhMzBhODYxMzI1MjBkYTM1ZTY3ZGFiMzhjYjVjODgwYWY3N2ZjNTEyMjA5OnA6RjpO&amp;a=Myriad+Genetics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:MYGN" idsrc="xmltag.org" >Myriad Genetics, Inc.</span></a>, (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with <span value="NYSE:AZN" idsrc="xmltag.org" >AstraZeneca</span> (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims http://www.streetinsider.com/PRNewswire/SOPHiA+GENETICS+and+Myriad+Genetics+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164650.html Thu, 08 Oct 2026 09:00:00 -0400 AZN MYGN SOPH http://www.streetinsider.com/Press+Releases/SOPHiA+GENETICS+and+Myriad+Genetics+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164650.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4792652-1&amp;h=2487028299&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fwww.sophiagenetics.com%2F___.YzJ1Om15cmlhZGdlbmV0aWNzOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmMwYjkyZTg4NmQ1ZGJiNjJlZTczMzJjZWY5MzhjNWZlOjc6OTcxZjo0YjU3ZmM5MTM4NjlmMmNlNzBhNjBkMDAzZjZiNmViMmQ4NmJmYmMzZGVkMDU1NDQ0N2JlNzYwNzk0MTAwODVhOnA6RjpO&amp;a=SOPHiA+GENETICS" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:SOPH" idsrc="xmltag.org" >SOPHiA GENETICS</span></a> (NASDAQ: SOPH) and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4792652-1&amp;h=1870734191&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fmyriad.com%2F___.YzJ1Om15cmlhZGdlbmV0aWNzOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmMwYjkyZTg4NmQ1ZGJiNjJlZTczMzJjZWY5MzhjNWZlOjc6OTY5MjpjNWExMzdiOWVkOTgyY2ZmYmI3YmNhMzBhODYxMzI1MjBkYTM1ZTY3ZGFiMzhjYjVjODgwYWY3N2ZjNTEyMjA5OnA6RjpO&amp;a=Myriad+Genetics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:MYGN" idsrc="xmltag.org" >Myriad Genetics, Inc.</span></a>, (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with <span value="NYSE:AZN" idsrc="xmltag.org" >AstraZeneca</span> (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims http://www.streetinsider.com/Press+Releases/SOPHiA+GENETICS+and+Myriad+Genetics+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164650.html Thu, 08 Oct 2026 09:00:00 -0400 AZN MYGN SOPH http://www.streetinsider.com/PRNewswire/SOPHiA+GENETICS+and+Myriad+Genetics+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164650.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.boston" idsrc="xmltag.org" >BOSTON</location></span>, <span class="legendSpanClass"><chron>Oct. 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4792652-1&amp;h=2487028299&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fwww.sophiagenetics.com%2F___.YzJ1Om15cmlhZGdlbmV0aWNzOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmMwYjkyZTg4NmQ1ZGJiNjJlZTczMzJjZWY5MzhjNWZlOjc6OTcxZjo0YjU3ZmM5MTM4NjlmMmNlNzBhNjBkMDAzZjZiNmViMmQ4NmJmYmMzZGVkMDU1NDQ0N2JlNzYwNzk0MTAwODVhOnA6RjpO&amp;a=SOPHiA+GENETICS" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:SOPH" idsrc="xmltag.org" >SOPHiA GENETICS</span></a> (NASDAQ: SOPH) and <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4792652-1&amp;h=1870734191&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fmyriad.com%2F___.YzJ1Om15cmlhZGdlbmV0aWNzOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmMwYjkyZTg4NmQ1ZGJiNjJlZTczMzJjZWY5MzhjNWZlOjc6OTY5MjpjNWExMzdiOWVkOTgyY2ZmYmI3YmNhMzBhODYxMzI1MjBkYTM1ZTY3ZGFiMzhjYjVjODgwYWY3N2ZjNTEyMjA5OnA6RjpO&amp;a=Myriad+Genetics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:MYGN" idsrc="xmltag.org" >Myriad Genetics, Inc.</span></a>, (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with <span value="NYSE:AZN" idsrc="xmltag.org" >AstraZeneca</span> (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims http://www.streetinsider.com/PRNewswire/SOPHiA+GENETICS+and+Myriad+Genetics+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164650.html Thu, 08 Oct 2026 09:00:00 -0400 AZN MYGN SOPH http://www.streetinsider.com/Press+Releases/Myriad+Genetics+and+SOPHiA+GENETICS+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164545.html <p align="left">SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=IDsL0wmmPRL7EvonNIgSykXlXMDn2J_Meq9L1zaMHMi9XrIdu0x43Zr6WgJGCTC7VlQJ2B6OaTqlYa45blym5hV9eY5zvTaYHb3HvuiIyGAqXxMvYCn05agyEW2PaltBt-CxTfn5cBWoolL1GWOtwf58vreqMn00nj74ShtCJiEyW00Wp6mzhN4cFpu0Rs1KwhbDRrHkiqZoTlqkI3uvENgmmxaXKrEDM3R4WKiOa4zzGTxj5TlbL8rlM8oRoYBx5S4MP_RW_dcP6LpceMxfJGpXX6f1Fxz9ocHG5Pdu2BL0DwxmwPcMp0hvTNfnyIQaZNbszw7RhvaoCVXMpaA7Bga2asqDVZCZHEjmfrOrEGEJ7gqwGNrS_FDWeQvvkAYrGepxUfzySQbPVNHLZJJCjf9iNX4GsmktN29vsH9NDxNjwMwVLVWEkuBDzH0zPAaq" rel="nofollow" target="_blank">Myriad Genetics, Inc.</a>, (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and <a href="https://www.globenewswire.com/Tracker?data=dXDVlEkaIz5V72ToNvYpJYl37dk7mDaEh2DyDqaFnuFlehMF7nzKdkExHXfqo3ehSfrtZObWPusTDMuaqB_T1bquzH_FirP_0i4EwBbE6V4FvCJ-EKGmLvPP-vTv5bT7b7bHCMw7BgM7zgjBRp8hmbDx5DTkl5oYq3uMQslpd8rPbD2lC-GutjzwmsZ6ulc6p8nNkGyD-cpYpDqVAJl_g3OzP34NqMfzuL9Jsk-9AhQOHzvKBraylKz1JKdVIXmf_2ELYV1cJmqx5334BQVZZQjJPyDSVv1Lb3DhyJj8tZ9MNnRgYQ2-ZLMgKCqCGmGxog_D_lhzreturSK3GT1FVxBwHnlHn3Wzkui_POzdzirlJvGbGg9AT_17jJebHhvAW9dYz0_0C3AO0SYJiAcVl09vxKzlk1_4p8gaWukqUPCkvnzEfB7yAsTrUGhlVkCW" rel="nofollow" target="_blank">SOPHiA GENETICS</a> (NASDAQ: SOPH) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through http://www.streetinsider.com/Press+Releases/Myriad+Genetics+and+SOPHiA+GENETICS+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164545.html Thu, 08 Oct 2026 09:00:00 -0400 AZN MYGN SOPH http://www.streetinsider.com/Globe+Newswire/Myriad+Genetics+and+SOPHiA+GENETICS+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164545.html <p align="left">SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=IDsL0wmmPRL7EvonNIgSykXlXMDn2J_Meq9L1zaMHMi9XrIdu0x43Zr6WgJGCTC7VlQJ2B6OaTqlYa45blym5hV9eY5zvTaYHb3HvuiIyGAqXxMvYCn05agyEW2PaltBt-CxTfn5cBWoolL1GWOtwf58vreqMn00nj74ShtCJiEyW00Wp6mzhN4cFpu0Rs1KwhbDRrHkiqZoTlqkI3uvENgmmxaXKrEDM3R4WKiOa4zzGTxj5TlbL8rlM8oRoYBx5S4MP_RW_dcP6LpceMxfJGpXX6f1Fxz9ocHG5Pdu2BL0DwxmwPcMp0hvTNfnyIQaZNbszw7RhvaoCVXMpaA7Bga2asqDVZCZHEjmfrOrEGEJ7gqwGNrS_FDWeQvvkAYrGepxUfzySQbPVNHLZJJCjf9iNX4GsmktN29vsH9NDxNjwMwVLVWEkuBDzH0zPAaq" rel="nofollow" target="_blank">Myriad Genetics, Inc.</a>, (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and <a href="https://www.globenewswire.com/Tracker?data=dXDVlEkaIz5V72ToNvYpJYl37dk7mDaEh2DyDqaFnuFlehMF7nzKdkExHXfqo3ehSfrtZObWPusTDMuaqB_T1bquzH_FirP_0i4EwBbE6V4FvCJ-EKGmLvPP-vTv5bT7b7bHCMw7BgM7zgjBRp8hmbDx5DTkl5oYq3uMQslpd8rPbD2lC-GutjzwmsZ6ulc6p8nNkGyD-cpYpDqVAJl_g3OzP34NqMfzuL9Jsk-9AhQOHzvKBraylKz1JKdVIXmf_2ELYV1cJmqx5334BQVZZQjJPyDSVv1Lb3DhyJj8tZ9MNnRgYQ2-ZLMgKCqCGmGxog_D_lhzreturSK3GT1FVxBwHnlHn3Wzkui_POzdzirlJvGbGg9AT_17jJebHhvAW9dYz0_0C3AO0SYJiAcVl09vxKzlk1_4p8gaWukqUPCkvnzEfB7yAsTrUGhlVkCW" rel="nofollow" target="_blank">SOPHiA GENETICS</a> (NASDAQ: SOPH) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through http://www.streetinsider.com/Globe+Newswire/Myriad+Genetics+and+SOPHiA+GENETICS+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164545.html Thu, 08 Oct 2026 09:00:00 -0400 AZN MYGN SOPH http://www.streetinsider.com/Press+Releases/Myriad+Genetics+and+SOPHiA+GENETICS+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164545.html <p align="left">SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=IDsL0wmmPRL7EvonNIgSykXlXMDn2J_Meq9L1zaMHMi9XrIdu0x43Zr6WgJGCTC7VlQJ2B6OaTqlYa45blym5hV9eY5zvTaYHb3HvuiIyGAqXxMvYCn05agyEW2PaltBt-CxTfn5cBWoolL1GWOtwf58vreqMn00nj74ShtCJiEyW00Wp6mzhN4cFpu0Rs1KwhbDRrHkiqZoTlqkI3uvENgmmxaXKrEDM3R4WKiOa4zzGTxj5TlbL8rlM8oRoYBx5S4MP_RW_dcP6LpceMxfJGpXX6f1Fxz9ocHG5Pdu2BL0DwxmwPcMp0hvTNfnyIQaZNbszw7RhvaoCVXMpaA7Bga2asqDVZCZHEjmfrOrEGEJ7gqwGNrS_FDWeQvvkAYrGepxUfzySQbPVNHLZJJCjf9iNX4GsmktN29vsH9NDxNjwMwVLVWEkuBDzH0zPAaq" rel="nofollow" target="_blank">Myriad Genetics, Inc.</a>, (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and <a href="https://www.globenewswire.com/Tracker?data=dXDVlEkaIz5V72ToNvYpJYl37dk7mDaEh2DyDqaFnuFlehMF7nzKdkExHXfqo3ehSfrtZObWPusTDMuaqB_T1bquzH_FirP_0i4EwBbE6V4FvCJ-EKGmLvPP-vTv5bT7b7bHCMw7BgM7zgjBRp8hmbDx5DTkl5oYq3uMQslpd8rPbD2lC-GutjzwmsZ6ulc6p8nNkGyD-cpYpDqVAJl_g3OzP34NqMfzuL9Jsk-9AhQOHzvKBraylKz1JKdVIXmf_2ELYV1cJmqx5334BQVZZQjJPyDSVv1Lb3DhyJj8tZ9MNnRgYQ2-ZLMgKCqCGmGxog_D_lhzreturSK3GT1FVxBwHnlHn3Wzkui_POzdzirlJvGbGg9AT_17jJebHhvAW9dYz0_0C3AO0SYJiAcVl09vxKzlk1_4p8gaWukqUPCkvnzEfB7yAsTrUGhlVkCW" rel="nofollow" target="_blank">SOPHiA GENETICS</a> (NASDAQ: SOPH) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through http://www.streetinsider.com/Press+Releases/Myriad+Genetics+and+SOPHiA+GENETICS+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164545.html Thu, 08 Oct 2026 09:00:00 -0400 AZN MYGN SOPH http://www.streetinsider.com/Globe+Newswire/Myriad+Genetics+and+SOPHiA+GENETICS+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164545.html <p align="left">SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=IDsL0wmmPRL7EvonNIgSykXlXMDn2J_Meq9L1zaMHMi9XrIdu0x43Zr6WgJGCTC7VlQJ2B6OaTqlYa45blym5hV9eY5zvTaYHb3HvuiIyGAqXxMvYCn05agyEW2PaltBt-CxTfn5cBWoolL1GWOtwf58vreqMn00nj74ShtCJiEyW00Wp6mzhN4cFpu0Rs1KwhbDRrHkiqZoTlqkI3uvENgmmxaXKrEDM3R4WKiOa4zzGTxj5TlbL8rlM8oRoYBx5S4MP_RW_dcP6LpceMxfJGpXX6f1Fxz9ocHG5Pdu2BL0DwxmwPcMp0hvTNfnyIQaZNbszw7RhvaoCVXMpaA7Bga2asqDVZCZHEjmfrOrEGEJ7gqwGNrS_FDWeQvvkAYrGepxUfzySQbPVNHLZJJCjf9iNX4GsmktN29vsH9NDxNjwMwVLVWEkuBDzH0zPAaq" rel="nofollow" target="_blank">Myriad Genetics, Inc.</a>, (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and <a href="https://www.globenewswire.com/Tracker?data=dXDVlEkaIz5V72ToNvYpJYl37dk7mDaEh2DyDqaFnuFlehMF7nzKdkExHXfqo3ehSfrtZObWPusTDMuaqB_T1bquzH_FirP_0i4EwBbE6V4FvCJ-EKGmLvPP-vTv5bT7b7bHCMw7BgM7zgjBRp8hmbDx5DTkl5oYq3uMQslpd8rPbD2lC-GutjzwmsZ6ulc6p8nNkGyD-cpYpDqVAJl_g3OzP34NqMfzuL9Jsk-9AhQOHzvKBraylKz1JKdVIXmf_2ELYV1cJmqx5334BQVZZQjJPyDSVv1Lb3DhyJj8tZ9MNnRgYQ2-ZLMgKCqCGmGxog_D_lhzreturSK3GT1FVxBwHnlHn3Wzkui_POzdzirlJvGbGg9AT_17jJebHhvAW9dYz0_0C3AO0SYJiAcVl09vxKzlk1_4p8gaWukqUPCkvnzEfB7yAsTrUGhlVkCW" rel="nofollow" target="_blank">SOPHiA GENETICS</a> (NASDAQ: SOPH) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through http://www.streetinsider.com/Globe+Newswire/Myriad+Genetics+and+SOPHiA+GENETICS+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164545.html Thu, 08 Oct 2026 09:00:00 -0400 AZN MYGN SOPH http://www.streetinsider.com/Press+Releases/Myriad+Genetics+and+SOPHiA+GENETICS+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164545.html <p align="left">SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=IDsL0wmmPRL7EvonNIgSykXlXMDn2J_Meq9L1zaMHMi9XrIdu0x43Zr6WgJGCTC7VlQJ2B6OaTqlYa45blym5hV9eY5zvTaYHb3HvuiIyGAqXxMvYCn05agyEW2PaltBt-CxTfn5cBWoolL1GWOtwf58vreqMn00nj74ShtCJiEyW00Wp6mzhN4cFpu0Rs1KwhbDRrHkiqZoTlqkI3uvENgmmxaXKrEDM3R4WKiOa4zzGTxj5TlbL8rlM8oRoYBx5S4MP_RW_dcP6LpceMxfJGpXX6f1Fxz9ocHG5Pdu2BL0DwxmwPcMp0hvTNfnyIQaZNbszw7RhvaoCVXMpaA7Bga2asqDVZCZHEjmfrOrEGEJ7gqwGNrS_FDWeQvvkAYrGepxUfzySQbPVNHLZJJCjf9iNX4GsmktN29vsH9NDxNjwMwVLVWEkuBDzH0zPAaq" rel="nofollow" target="_blank">Myriad Genetics, Inc.</a>, (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and <a href="https://www.globenewswire.com/Tracker?data=dXDVlEkaIz5V72ToNvYpJYl37dk7mDaEh2DyDqaFnuFlehMF7nzKdkExHXfqo3ehSfrtZObWPusTDMuaqB_T1bquzH_FirP_0i4EwBbE6V4FvCJ-EKGmLvPP-vTv5bT7b7bHCMw7BgM7zgjBRp8hmbDx5DTkl5oYq3uMQslpd8rPbD2lC-GutjzwmsZ6ulc6p8nNkGyD-cpYpDqVAJl_g3OzP34NqMfzuL9Jsk-9AhQOHzvKBraylKz1JKdVIXmf_2ELYV1cJmqx5334BQVZZQjJPyDSVv1Lb3DhyJj8tZ9MNnRgYQ2-ZLMgKCqCGmGxog_D_lhzreturSK3GT1FVxBwHnlHn3Wzkui_POzdzirlJvGbGg9AT_17jJebHhvAW9dYz0_0C3AO0SYJiAcVl09vxKzlk1_4p8gaWukqUPCkvnzEfB7yAsTrUGhlVkCW" rel="nofollow" target="_blank">SOPHiA GENETICS</a> (NASDAQ: SOPH) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through http://www.streetinsider.com/Press+Releases/Myriad+Genetics+and+SOPHiA+GENETICS+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164545.html Thu, 08 Oct 2026 09:00:00 -0400 AZN MYGN SOPH http://www.streetinsider.com/Globe+Newswire/Myriad+Genetics+and+SOPHiA+GENETICS+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164545.html <p align="left">SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=IDsL0wmmPRL7EvonNIgSykXlXMDn2J_Meq9L1zaMHMi9XrIdu0x43Zr6WgJGCTC7VlQJ2B6OaTqlYa45blym5hV9eY5zvTaYHb3HvuiIyGAqXxMvYCn05agyEW2PaltBt-CxTfn5cBWoolL1GWOtwf58vreqMn00nj74ShtCJiEyW00Wp6mzhN4cFpu0Rs1KwhbDRrHkiqZoTlqkI3uvENgmmxaXKrEDM3R4WKiOa4zzGTxj5TlbL8rlM8oRoYBx5S4MP_RW_dcP6LpceMxfJGpXX6f1Fxz9ocHG5Pdu2BL0DwxmwPcMp0hvTNfnyIQaZNbszw7RhvaoCVXMpaA7Bga2asqDVZCZHEjmfrOrEGEJ7gqwGNrS_FDWeQvvkAYrGepxUfzySQbPVNHLZJJCjf9iNX4GsmktN29vsH9NDxNjwMwVLVWEkuBDzH0zPAaq" rel="nofollow" target="_blank">Myriad Genetics, Inc.</a>, (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and <a href="https://www.globenewswire.com/Tracker?data=dXDVlEkaIz5V72ToNvYpJYl37dk7mDaEh2DyDqaFnuFlehMF7nzKdkExHXfqo3ehSfrtZObWPusTDMuaqB_T1bquzH_FirP_0i4EwBbE6V4FvCJ-EKGmLvPP-vTv5bT7b7bHCMw7BgM7zgjBRp8hmbDx5DTkl5oYq3uMQslpd8rPbD2lC-GutjzwmsZ6ulc6p8nNkGyD-cpYpDqVAJl_g3OzP34NqMfzuL9Jsk-9AhQOHzvKBraylKz1JKdVIXmf_2ELYV1cJmqx5334BQVZZQjJPyDSVv1Lb3DhyJj8tZ9MNnRgYQ2-ZLMgKCqCGmGxog_D_lhzreturSK3GT1FVxBwHnlHn3Wzkui_POzdzirlJvGbGg9AT_17jJebHhvAW9dYz0_0C3AO0SYJiAcVl09vxKzlk1_4p8gaWukqUPCkvnzEfB7yAsTrUGhlVkCW" rel="nofollow" target="_blank">SOPHiA GENETICS</a> (NASDAQ: SOPH) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through http://www.streetinsider.com/Globe+Newswire/Myriad+Genetics+and+SOPHiA+GENETICS+Announce+New+Collaboration+to+Advance+Prostate+Genomic+Instability+Score+Technology/27164545.html Thu, 08 Oct 2026 09:00:00 -0400 AZN MYGN SOPH http://www.streetinsider.com/Analyst+PT+Change/Myriad+Genetics+%28MYGN%29+PT+Raised+to+%248+at+Craig-Hallum/27139574.html Craig-Hallum analyst John Wilkin raised the price target on Myriad Genetics (NASDAQ: MYGN) to $8.00 (from $4.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Myriad+Genetics+%28MYGN%29+PT+Raised+to+%248+at+Craig-Hallum/27139574.html Fri, 02 Oct 2026 09:22:18 -0400 MYGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MYRIAD+GENETICS+INC+++++++For%3A+Sep+21++Filed+by%3A+Wheeler+Benjamin+Richard/27091175.html si-local-file:///var/storage/secattach/20260922/27091175.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MYRIAD+GENETICS+INC+++++++For%3A+Sep+21++Filed+by%3A+Wheeler+Benjamin+Richard/27091175.html Tue, 22 Sep 2026 16:12:00 -0400 MYGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MYRIAD+GENETICS+INC+++++++For%3A+Sep+16++Filed+by%3A+Donnelly+Brian+J/27080742.html si-local-file:///var/storage/secattach/20260918/27080742.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MYRIAD+GENETICS+INC+++++++For%3A+Sep+16++Filed+by%3A+Donnelly+Brian+J/27080742.html Fri, 18 Sep 2026 16:17:00 -0400 MYGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MYRIAD+GENETICS+INC+++++++For%3A+Sep+16++Filed+by%3A+Sikri+Vishal/27076363.html si-local-file:///var/storage/secattach/20260917/27076363.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MYRIAD+GENETICS+INC+++++++For%3A+Sep+16++Filed+by%3A+Sikri+Vishal/27076363.html Thu, 17 Sep 2026 16:34:00 -0400 MYGN http://www.streetinsider.com/SEC+Filings/Form++3++++++++++MYRIAD+GENETICS+INC+++++++For%3A+Sep+16++Filed+by%3A+Sikri+Vishal/27076306.html si-local-file:///var/storage/secattach/20260917/27076306.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++MYRIAD+GENETICS+INC+++++++For%3A+Sep+16++Filed+by%3A+Sikri+Vishal/27076306.html Thu, 17 Sep 2026 16:31:00 -0400 MYGN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MYRIAD+GENETICS+INC+++++++For%3A+Sep+15/27067711.html si-local-file:///var/storage/secattach/20260916/27067711.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MYRIAD+GENETICS+INC+++++++For%3A+Sep+15/27067711.html Wed, 16 Sep 2026 08:01:00 -0400 MYGN